1-4 of 4
Laura Rassenti, Ph.D.
Close
Sort by
Journal Articles

Rituximab and High-Dose Methylprednisolone for the Initial Treatment of Chronic Lymphocytic Leukemia Is Associated with Promising Clinical Activity and Minimal Hematologic Toxicity

Aanelle F James, M.D., Januario E. Castro, M.D., Jose David Sandoval-Sus, M.D., Sonia Jain, Ph.D., Janet Bole, R.N., Laura Rassenti, Ph.D., Thomas J. Kipps, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 47.
https://doi.org/10.1182/blood.V112.11.47.47
Published: 2008
Journal Articles

CLLU1, a Novel Molecular Marker for Minimal Residual Disease Monitoring in Chronic Lymphocytic Leukemia

Danelle James, M.D., Esther D Avery, Laura Rassenti, Ph.D., Thomas J. Kipps, M.D., Ph.D., Anne Mette Buhl, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 3158.
https://doi.org/10.1182/blood.V112.11.3158.3158
Published: 2008
Journal Articles

Autoantibodies Against p53 Are Associated with p17 Deletions in CLL.

Bradley T. Messmer, PhD, Talia S. Nour-Omid, Emanuela Ghia, Ph.D., Laura Rassenti, Ph.D., Thomas J. Kipps, M.D./Ph.D.
Journal: Blood
Blood (2007) 110 (11): 2066.
https://doi.org/10.1182/blood.V110.11.2066.2066
Published: 2007
Journal Articles

A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens.

Januario E. Castro, MD, Olivier J. Loria, B.S, Robier A. Aguillon, M.D, Danelle James, M.D, Cesar A. Llanos, M.D, M.Sc, Laura Rassenti, Ph.D, Brian A. Wood, B.S, Jon T. Homlund, M.D, Thomas J. Kipps, M.D, Ph.D
Journal: Blood
Blood (2007) 110 (11): 3119.
https://doi.org/10.1182/blood.V110.11.3119.3119
Published: 2007